These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 9248609)

  • 1. FDA position on product selection for 'narrow therapeutic index' drugs.
    Am J Health Syst Pharm; 1997 Jul; 54(14):1630-2. PubMed ID: 9248609
    [No Abstract]   [Full Text] [Related]  

  • 2. In U.S., biosimilars still await FDA decision.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Apr; 98(7):435. PubMed ID: 16595775
    [No Abstract]   [Full Text] [Related]  

  • 3. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract]   [Full Text] [Related]  

  • 4. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

  • 5. Generic drug product equivalence: current status.
    Meyer MC
    Am J Manag Care; 1998 Aug; 4(8):1183-9; quiz 1190-2. PubMed ID: 10182892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficiencies of the FDA in evaluating generic formulations: addressing narrow therapeutic index drugs.
    Hottinger M; Liang BA
    Am J Law Med; 2012; 38(4):667-89. PubMed ID: 23356099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NerveCenter: FDA requirements for generic drug applications.
    Ann Neurol; 2010 Sep; 68(3):A11. PubMed ID: 20818779
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessing the safety and comparative effectiveness of follow-on biologics (biosimilars) in the United States.
    Hennessy S; Leonard CE; Platt R
    Clin Pharmacol Ther; 2010 Feb; 87(2):157-9. PubMed ID: 20107450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of the biosimilar pathway: economic and policy issues.
    Grabowski H; Long G; Mortimer R
    Seton Hall Law Rev; 2011; 41(2):511-57. PubMed ID: 21739758
    [No Abstract]   [Full Text] [Related]  

  • 10. The generic drug approval process.
    Rheinstein PH
    Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762
    [No Abstract]   [Full Text] [Related]  

  • 11. A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways.
    Klein K; Borchard G; Shah VP; Flühmann B; McNeil SE; de Vlieger JSB
    Ann N Y Acad Sci; 2021 Oct; 1502(1):5-13. PubMed ID: 34296458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promise and Peril for Generic Drugs.
    Sharfstein JM; Greene J
    JAMA Intern Med; 2016 Jun; 176(6):733-4. PubMed ID: 27159885
    [No Abstract]   [Full Text] [Related]  

  • 14. Hatch-Waxman Turns 30: Do We Need a Re-Designed Approach for the Modern Era?
    Kesselheim AS; Darrow JJ
    Yale J Health Policy Law Ethics; 2015; 15(2):293-347. PubMed ID: 26333236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Takings issues in the approval of generic biologics.
    Yoo JC
    Food Drug Law J; 2005; 60(1):33-43. PubMed ID: 15940853
    [No Abstract]   [Full Text] [Related]  

  • 16. Decision Science for Generic Drug Development and Review.
    Lionberger R
    J Clin Pharmacol; 2019 Sep; 59(9):1249-1251. PubMed ID: 31087559
    [No Abstract]   [Full Text] [Related]  

  • 17. A generic drug primer: regulatory aspects and scientific concepts.
    Henderson JD; White GL
    Mil Med; 1998 Apr; 163(4):193-7. PubMed ID: 9575760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability and bioequivalence: an FDA regulatory overview.
    Chen ML; Shah V; Patnaik R; Adams W; Hussain A; Conner D; Mehta M; Malinowski H; Lazor J; Huang SM; Hare D; Lesko L; Sporn D; Williams R
    Pharm Res; 2001 Dec; 18(12):1645-50. PubMed ID: 11785681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress and Hurdles for Follow-on Biologics.
    Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2015 Jun; 372(25):2380-2. PubMed ID: 25946143
    [No Abstract]   [Full Text] [Related]  

  • 20. GATT implementation and generic drug approval.
    Safir PO; Lassman SM
    Food Drug Law J; 1996; 51(2):295-302. PubMed ID: 11820203
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.